Agency for Medicinal Products and Medical Devices of the Republic of Slovenia
Since its launch on January 1, 2024, the IncreaseNET project has been making steady progress, focusing on enhancing the capabilities and collaboration among European medicines regulatory authorities. In the first […]
IncreaseNET: A Six-Month Progress Overview Read More »
We are pleased to announce the launch of a new version of the Clinical Trials Information System (CTIS) public portal, which will allow earlier and more efficient access to clinical
New version of the Clinical Trials Information System (CTIS) public portal Read More »
Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP) reiterates its invitation to marketing authorisation holders to provide information about the product codes (PC) used in
CT CURE, the European Union (EU) joint action seeking ways to expedite assessment and decisions on multinational clinical trial applications related to COVID-19 therapeutics, has entered its final year. The
Agency for medical products and medical devices of the Republic of Slovenia is committed to continuous improvement of its performance and has been actively participating in the Benchmarking of European
Benchmarking of European Medicines Agencies – BEMA Read More »
31 January 2024 was an important day for the entire European medicines regulatory network. The kick-off meeting of the Joint Action (JA) Supporting the increased capacity and competence building of
Kick-off meeting of the IncreaseNET Joint Action Read More »
The Agency of the Republic of Slovenia for Medicinal Products and Medical Devices (JAZMP) has taken over the role of coordinator of the Joint Action (JA) Project Supporting the increased
IncreaseNET project accepted for co-funding under the EU4Health programme Read More »
According to Article 58(12) of Regulation (EU) 2019/6, all Marketing Authorisation Holders must submit the annual Volume of Sales for each veterinary medicinal product to the Union Product Database (UPD).
The Agency for Medicines and Medical Devices of the Republic of Slovenia (JAZMP) and the Icelandic Medicines Agency – Lyfjastofnun (IMA) have signed a long-term agreement in the field of
JAZMP is ambitious to further actively participate in assessment of marketing authorisation applications. In order to strengthen Slovenia’s position in the regulatory EU environment, one of the strategic objectives of
JAZMP AVAILABLE TO ACT AS REFERENCE MEMBER STATE (RMS) IN MRP AND DCP PROCEDURES Read More »
